Nivolumab as Single-Agent Treatment for BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Source: The ASCO Post, December 2015
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.
On November 24, 2015, nivolumab (Opdivo) was approved for use as a single agent in the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.1 Nivolumab has prior approvals in unresectable or metastatic melanoma for use as a single agent in patients with BRAF V600 mutation–positive disease and disease progression following treatment with ipilimumab (Yervoy) and a BRAF inhibitor and in combination with ipilimumab in patients with BRAF V600 wild-type disease.